Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 156

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 156
---
 | 474,407 |     |           | 611,905 |
| Jamie Platt     |     |                  | 26,875 |     |                     | 112,498 |     |                  |       — |     |           | 139,373 |

| (1) | Amounts                                                                                                                            
 do not reflect compensation actually received by the directors. Instead, the amounts represent aggregate grant date fair value of  
 the restricted stock award computed in accordance with ASC 718, Stock Compensation. The valuation assumptions used in determining  
 such amounts are consistent with those described in Note 11 of the Company’s Consolidated Financial Statements, included elsewhere 
 in this prospectus. As of December 31, 2024, the aggregate number of outstanding options, all of which are currently exercisable,  
 held by each individual who served as a non-NEO director during 2024 was as follows: Robert Anderson – 39,281; Stuart Diamond      
 – 7,142; Peter Knight – 28,568; Gary Rubin – 32,139; Roby Joyce – 0; and Jamie Platt – 0. As of December                           
 31, 2024, the aggregate number of unvested shares of restricted stock held by each non-NEO director was 8,449.                     |

| 74 |

<div align='center'>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</div>

Related-Party Transactions

In addition to the compensation arrangements with directors and executive officers described under “Executive and Director Compensation,” the following is a description of each transaction since January 1, 2023, and each currently proposed transaction in which:

| ● | the                                                                                                                        
 Company was or is to be a participant;                                                                                     |
| ● | the                                                                                                                        
 amount involved exceeds the lesser of $120,000 or one percent of the average of the Company’s total assets at year end for 
 the last two completed fiscal years; and                                                                                   |
| ● | any                                                                                                                        
 related person had or will have a direct or indirect material interest.                                                    |

PPLS Acquisition of the Laboratory

On September 18, 2023, the Company’s wholly owned subsidiary, PPLS, consummated the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, pursuant to the terms of the Asset Purchase Agreement with Village Oaks. As a result of the acquisition, the CAP-accredited, CLIA-certified clinical